Hit to lead
Early in vivo validation of antimalarial hits
EARLY IN VIVO
PROOF-OF-CONCEPT
Determine pharmacological effect in a complex system before committing heavy resources to optimization
BENCHMARKING AGAINST
KNOWN DRUGS
Compare compound profiles to existing therapies, anticipating mechanism of action and clinical positioning.
ACCELERATED
DECISION-MAKING
Avoid wasting 6–12 months optimizing a series that lacks in vivo viability.
FEWER LATE-STAGE
FAILURES
Early in vivo predictive models reduce risk during clinical translation.
OBJECTIVE
PRIORITIZATION
Decisions are driven by measurable in vivo data, not only SAR or theorical data.
Do you have a compound in this phase?
Which TAD services can help you to move forward?
Proof Of Concept
in TADHuMouse®-Pfalc
A small dose fractionation PK/PD study to show how your chemical series could work in vivo and learning how to tailor optimal in vivo preclinical studies for that chemical family.
Main outcomes
Parasite Stage susceptibility
Which stage is most sensitive to treatment?
Maximum parasite clearance
Is it a fast, slow or very slow treatment in vivo?
Preliminary oral PK
What is the best schedule of treatment and dose range to optimally test your treatment in TADhuMouse® in vivo?
Tolerability and potential adverse
effects
How is the best way to analyze the treatment in TADhuMouse ® in vivo?
Benchmarking with standard
antimalarials
Where the new treatment maps in efficacy compared to standard antimalarials?